The presymptomatic stage of neurodegenerative disorders;Das präsymptomatische Stadium neurodegenerativer Erkrankungen

Nervenarzt

Volumn 82, Issue 8, 2011, Pages 994-1001

  Klein, C ^a   Hagenah, J ^a   Landwehrmeyer, B ^b   Munte T ^a   Klockgether, T ^c,d  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; Neurodegenerative disorders; Parkinson's disease; Presymptomatic stage; Trinucleotide repeat expansion disorders

Indexed keywords

ARTICLE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE SEVERITY; HUMAN; ONSET AGE; PARKINSON DISEASE; SENSITIVITY ANALYSIS;

ADULT; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENDOPHENOTYPES; GENETIC MARKERS; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SPINOCEREBELLAR ATAXIAS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 80755139417     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-011-3258-y     Document Type: Article

References (31)

1. Halliday GM, Fedorow H, Rickert CH et al (2006) Evidence for specific phases in the development of human neuromelanin. J Neural Transm 113(6): 721-728 (Pubitemid 43847164)
2. Klein C, Krainc D, Schlossmacher MG, Lang AE (2011) Translational research in neurology and neuroscience 2011: movement disorders. Arch Neurol (in press)
3. Paulson HL, Fischbeck KH (1996) Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 19:79-107 (Pubitemid 26080823)
4. Bruggemann N, Vegt J, Klein C, Siebner HR (2010) Imaging of genetic aspects of Parkinson's disease. Nervenarzt 81 (10):1196-1203
5. Nuenen BF van, Weiss MM, Bloem BR et al (2009) Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 72(12):1041-1047
6. Vaccarino AL, Anderson K, Borowsky B et al (2011) An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in Huntington disease gene expansion carriers. Mov Disord 26(5):877-884
7. Paulsen JS, Langbehn DR, Stout JC et al (2008) Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79(8):874-880
8. Tabrizi SJ, Langbehn DR, Leavitt BR et al (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791-801
9. Tabrizi SJ, Scahill RI, Durr A et al (2011) Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10(1):31-42
10. Sturrock A, Laule C, Decolongon J et al (2010) Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 75(19): 1702-1710
11. Durr A (2010) Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 9(9):885-894
12. Schmitz-Hubsch T, Coudert M, Bauer P et al (2008) Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 71(13):982-989
13. Jacobi H, Bauer P, Giunti P et al (2011) The natural-history of spinocerebellar ataxia type1, 2, 3, and 6: a 2-year follow-up study. Neurology (in press)
14. Globas C, Montcel ST du, Baliko L et al (2008) Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord 23(15):2232-2238
15. Velazquez-Perez L, Diaz R, Perez-Gonzalez R et al (2009) Motor decline in clinically presymptomatic spinocerebellar ataxia type 2 gene carriers. PLoS One 4(4):e5398
16. Rodriguez-Labrada R, Velazquez-Perez L, Ochoa NC et al (2011) Subtle rapid eye movement sleep abnormalities in presymptomatic spinocerebellar ataxia type 2 gene carriers. Mov Disord 26(2):347-350
17. Christova P, Anderson JH, Gomez CM (2008) Impaired eye movements in presymptomatic spinocerebellar ataxia type 6. Arch Neurol 65(4):530-536 (Pubitemid 351549964)
18. Nalls MA, Plagnol V, Hernandez DG et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377(9766):641-649
19. Eggers C, Schmidt A, Hagenah J et al (2010) Progression of subtle motorsigns in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 74(22):1798-1805
20. Baba T, Takeda A, Kikuchi A et al (2011) Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. Mov Disord 26(4):621-628
21. Fujishiro H, Frigerio R, Burnett M et al (2008) Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 23(8):1085-1092
22. Postuma RB, Gagnon JF, Montplaisir J (2011) Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 81 (9):1008-1013
23. Berg D (2011) Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm118(4):613-619
24. Hagenah JM, Becker B, Bruggemann N et al (2008) Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations. J Neurol Neurosurg Psychiatry 79(9):1071-1074
25. Della Sala S, Cocchini G, Logie RH et al (2010) Dual task during encoding, maintenance, and retrieval in Alzheimer's disease. J Alzheimers Dis 19(2):503-515
26. Braak E, Griffing K, Arai K et al (1999) Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 249(Suppl 3):14-22
27. Wang PN, Lirng JF, Lin KN et al (2006) Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan. Neurobiol Aging 27(12):1797-1806 (Pubitemid 44572576)
28. Lerch JP, Pruessner J, Zijdenbos AP et al (2008) Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging 29(1):23-30 (Pubitemid 350110605)
29. Zhou J, Greicius MD, Gennatas ED et al (2010) Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 133(5):1352-1367
30. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2(10):605-613 (Pubitemid 37162569)
31. Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228-234 (Pubitemid 43238346)